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INTRODUCTION
Sodium is the major circulating cation. Plasma con-
centration is maintained within a tight physiological 
range. The regulation of sodium balance, water balance 
and circulating volume are linked and are best viewed as 
overlapping, co-ordinated neuro-humoral systems.
Plasma sodium concentration reflects the balance 
between sodium and water content. Each component 
reflects the balance of intake and output. This approach 
can be used to develop a framework for classifying 
hyponatraemia by aetiology. While such a framework has 
merits, it is important to recognise that hyponatraemia 
is often multifactorial.
Regulation of plasma volume and osmolality
Given that water content is a key determinant of plasma 
sodium concentration, it is intuitive that a breakdown in 
the relationship between water intake and water 
excretion could be one of the mechanisms underpinning 
hyponatraemia. The physiology of water balance thus 
serves to highlight the pathophysiological processes 
through which hyponatraemia can develop.
Water resorption by the distal nephron involves the 
movement of water from the lumen of the collecting 
duct into the renal interstitium. This requires both an 
osmolar gradient and functioning aquaporin 2 (AQP2) 
water channels on the luminal surface of collecting duct 
cells. The expression of AQP2 is dependent on the 
posterior pituitary hormone vasopressin (AVP).
Plasma osmolality is the major determinant of AVP 
secretion.  Above a functional osmolar threshold of 
some 285 mOsm/kg,  AVP secretion increases linearly 
in response to increments in plasma osmolality. If fluid 
volumes greater than those demanded by thirst are 
consumed, AVP secretion is suppressed to very low 
levels (<0.3 pmol/l), at which the kidney is capable of 
excreting 15–20 l of urine in 24 hours. Ingestion of fluid 
volumes in excess of this results in progressive lowering 
of plasma sodium.
Given the key role of AVP in reducing renal free water 
excretion, it is easy to see that inappropriate excess 
production of this hormone could lead to the development 
of hyponatraemia through haemodilution. While such 
inappropriate AVP production is one of the key mecha-
nisms of hyponatraemia, AVP is an important agent in 
mediating hyponatraemia in other circumstances too.
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Pseudohyponatraemia
 
Reduced renal free water 
clearance
• Hyperglycaemia
• Non-physiological osmolyte
Hypo-
volaemia
• Drugs
• Renal failure
• Portal  
  hypertension and  
  ascites
• Hypoalbuminaemia
• Sepsis and  
  vascular leak  
  syndromes
• Central salt wasting
• Fluid sequestration
Sodium depletion
Renal 
loss 
• Diuretics 
• Salt-wasting  
  nephropathy
• Hypoadrenalism
• Central salt  
  wasting
Extra-
renal loss 
• Gut loss
Excess water intake Other • Cardiac failure
• Nephrotic  
  syndrome
• Hypothyroidism
• Hypoadrenalism
• Hypopituitarism
• Syndrome of  
  inappropriate  
  antidiuresis (SIAD)
• Nephrogenic SIAD
• Excess use of  
   AVP analogues  
  (desmopressin  
  [DDAVP] oxytotics)
• Dipsogenic DI
• Sodium-free, hyposomolar 
  irrigant solutions
• Dilute infant feeding  
  formula
• Inappropriate intravenous 
  fluid therapy (excess  
  hypotonic fluid in relation  
  to water excretion; or  
  incorrect solute content)
TABLE 1 Classification of hyponatraemia
Hypotension and circulating volume depletion also 
stimulate AVP secretion (baro- and volume regulation). 
Indeed, non-osmoregulated AVP release can occur 
below the standard osmolar threshold. Hypotension or 
volume depletion can thus lead to persistent reduction 
in renal free water clearance despite ensuing 
hyponatraemia. AVP secretion in this context is 
physiological and can both initiate and maintain significant 
hyponatraemia if the deficit in circulating volume persists. 
This is a common mechanism for hyponatraemia in 
clinical practice.
AETIOLOGY OF HYPONATRAEMIA (see Table 1)
Intravascular volume depletion
Intravascular volume depletion from long-term diuretic 
use can produce significant hyponatraemia of 105–
125 mmol/l. Because hyponatraemia may develop slowly, 
patients can be relatively asymptomatic. Those on thiazide 
diuretics are particularly at risk as these agents produce 
solute, and thus plasma volume loss, without limiting renal 
concentrating ability. Renal water resorption capacity is 
not affected. Volume-stimulated AVP release can produce 
profound hyponatraemia in this context. While loop 
diuretics lead to significant solute loss, their site of action 
leads to a reduced intramedullary solute concentration 
gradient. Maximal renal concentrating ability is impaired, 
and water resorption produced by the action of volume-
stimulated AVP is limited. Inhibitors of renin–angiotensin 
system (RAS) action can also cause hyponatraemia 
through an effective reduction in circulating volume.
Portal hypertension, congestive cardiac failure and hypo-
albuminaemia can all reduce effective circulating volume 
independent of drug treatment and all can produce 
hyponatraemia through stimulating non-osmoregulated 
AVP production and renal water resorption, even in the 
context of excess total body sodium.
Central salt wasting
This acquired primary natriuresis is a rare cause of 
hyponatraemia with hypovolaemia. The underlying 
mechanism(s) remains unclear, but may involve increased 
release of natriuretic peptides and/or reduced 
sympathetic drive. Central salt wasting (CSW) is seen 
following a variety of neurosurgical situations. Diagnosis 
hinges on the natural history of the process: the 
development of hyponatraemia is preceded by natriuresis 
and diuresis with ensuing clinical and biochemical 
features of hypovolaemia. Central salt wasting is a 
particular concern for the neurosurgical patient in 
whom autoregulation of cerebral blood flow is disturbed 
and in whom small reductions in circulating volume can 
reduce cerebral perfusion. Syndrome of inappropriate 
antidiuresis (SIAD) can occur in the same group of 
patients.  As management of the two conditions is 
diametrically opposed, it is important to make the 
correct differential diagnosis.
Excess hypotonic fluid intake
The administration or absorption of hypotonic fluids at a 
rate that exceeds renal free water excretion will inevitably 
result in hyponatraemia. This can be seen with oral fluid 
intake (dipsogenic diabetes insipidus), intravenous fluid 
therapy and the absorption of hypotonic irrigating fluids 
following surgery to the lower renal tract.
Syndrome of inappropriate antidiuresis
In SIAD there is a failure to maximally suppress AVP 
secretion as plasma osmolality falls below the normal 
osmotic threshold for AVP release.  Absolute AVP values 
may not be particularly elevated.  As patients continue to 
drink, persistent antidiuresis produces dilutional 
hyponatraemia.  A diagnosis of SIAD involves the 
exclusion of volume depletion and other endocrine 
causes of reduced free water excretion (see Table 2). 
While emphasis is often placed on urine osmolality 
exceeding plasma osmolality, osmolar criteria for SIAD 
are met simply if urine is not maximally dilute in 
the face of coincident hyponatraemia (urine >100 
mOsm/kg in adults).
The majority of patients with SIAD are euvolaemic on 
clinical examination. This reflects two factors: the 
difficulty in identifying mild abnormalities of volume 
status on clinical examination and the homeostatic 
response to persistent SIAD. Syndrome of inappropriate 
antidiuresis can result in a negative sodium balance; urine 
sodium concentration is often above 80 mmol/l. This 
natriuresis may serve to limit volume expansion and is 
also important when considering the differential diagnosis 
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Hyponatraemia
Urine Osm >100 mOsm/kg
• sub-maximum dilution
Urine Na+ > 20 mmol/l
Absence of
• hypotension and hypovolaemia
• non-osmotic stimuli for AVP release
• oedema       
• adrenal failure
• hypothyroidism
TABLE 2 Syndrome of inappropriate antidiuresis: 
diagnostic characteristics
TABLE 3 Syndrome of inappropriate antidiuresis: sub-types
Type Characteristics of AVP release
A • AVP release independent of plasma osmolality
B • i Osmotic threshold for AVP release 
• Osmoregulation around i osmolar set point
C • Failure to suppress AVP at low osmolality 
• Normal response to osmotic stimulation
D • Normal osmoregulated AVP release
• Unable to excrete water load
of CSW. Four distinct patterns of AVP release have been 
characterised in SIAD (see Table 3).
Many drugs used in everyday clinical practice cause SIAD, 
and drug histories are an important part of the clinical 
assessment of patients presenting with hyponatraemia 
(see Table 4). Hyponatraemia secondary to SIAD is found 
in many patients taking anticonvulsants. Hyponatraemia 
can develop within a few days of commencing treatment 
with selective serotonin reuptake inhibitors (SSRIs).
Exercise-associated hyponatraemia (EAH)
Extreme endurance exercise produces significant non-
osmoregulated AVP release and reduced renal blood 
flow. Extreme endurance exercise is thus an antidiuretic 
state. If endurance athletes maintain a fluid intake in 
excess of free water clearance, hyponatraemia will 
ensue. This can be further complicated if there is 
aggressive fluid resuscitation in the event of collapse. 
The odds ratio for developing hyponatraemia is positively 
correlated with the length of time taken to complete the 
event and weight gain over the course of the event. 
The latter clearly implicates water intake in excess of 
water loss. Athletes need to be advised to follow their 
thirst as they run rather than simply taking on fluid.
Nephrogenic SIAD
The action of AVP on renal water excretion is mediated 
by the G-protein-coupled type 2 AVP-receptor (V2-R). 
Loss of function mutations of the V2-R are the cause of 
X-linked nephrogenic diabetes insipidus. Recent studies 
have identified the reciprocal phenotype: mutations in 
the V2-R that are constitutively activating, leading to 
AVP-independent but V2-R-mediated antidiuresis with 
persistent hyponatraemia.
MANAGEMENT: THE ISSUES
Principles and overview
While hyponatraemia can be life-threatening, chronic 
hyponatraemia can be tolerated very well even when 
profound.  This diversity poses a challenge in management: 
clinicians must balance the clinical efficacy of any 
intervention with the potential adverse impact of both 
the intervention and persisting hyponatraemia.
Hyponatraemia leads to discrete adaptations within the 
central nervous system (CNS) that aim to minimise 
brain swelling and preserve neuronal function. The initial 
response is an efflux of low molecular weight inorganic 
osmolytes from glial cells into the extracellular space/
cerebrospinal fluid. The timescale of this response is 
over hours. If hyponatraemia persists, the generation and 
efflux of organic osmolytes follow. This latter process 
occurs over days. Both responses reduce intracellular 
osmolality in an effort to limit net water movement into 
brain cells. Hyponatraemia of a magnitude that exceeds 
the capacity of this adaptive response, or develops at a 
rate that exceeds the rate of adaptation, is likely to be 
associated with significant neuronal dysfunction and 
hence symptoms.  Adaptive responses are critical factors 
in determining the approach to intervention. Rapid 
correction of hyponatraemia to which longer-term brain 
adaptation has occurred can result in significant osmolar 
stress to neurones and trigger osmotic demyelination.
The difficulty with many published approaches to the 
management of hyponatraemia lies in the translation to 
clinical practice. Volume overload and volume depletion 
can be apparent on clinical examination or become 
apparent within hours of presentation. However, in many 
cases it is difficult to determine volume status on clinical 
grounds. Drugs used for co-morbid conditions can make 
the interpretation of diagnostic testing for volume status 
difficult or impossible. Management guidance based on 
duration of hyponatraemia is equally problematic. In the 
majority of patients it is not possible to determine the 
duration of the problem. Moreover, pre-existing co- 
morbidities may make it difficult to be clear what 
contribution the electrolyte disturbance is making to the 
clinical picture.
While balancing diagnostic uncertainty and the risks and 
benefits of different management strategies must temper 
the clinician’s response, they need not paralyse it. Rather, 
they should focus the clinician on the task of prioritisation 
and identifying the appropriate therapeutic target: 
reversing or reducing morbidity and mortality associated 
with hyponatraemia while avoiding complications of 
treatment. The patient with mild morbidity does not 
require a non-specific intervention associated with a risk 
that exceeds that of a more conservative approach. In this 
situation, there may well be the time to further the 
differential diagnosis such that a tailored intervention, 
associated with a lower risk of adverse effects, is possible. 
Conversely, the patient presenting with seizure or 
significant coma requires a different approach; a 
conservative strategy could result in exposure to the risk 
of worsening neurological morbidity that exceeds the risk 
of intervention. In this scenario there may not be time to 
reach a definitive diagnosis of aetiology before action is 
required. However, the aim of management should not be 
achieving a normal plasma sodium level. Rather, it should 
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TABLE 4 Drugs commonly associated with SIAD
Antidepressants Tricyclic antidepressants
SSRIs
Dopamine antagonists Metoclopramide
Prochlorperazine
Antipsychotics
Anticonvulsants Carbamazepine
Phenytoin
Sodium valproate
Opiates
be achieving a plasma sodium level that reverses or 
reduces morbidity (e.g. stops seizures, improves coma) at 
such a rate that minimises risk of osmotic demyelination. 
There must be a stratified approach based on clinical 
presentation, balancing influences to achieve the best 
outcome (see Figure 1).
General and supportive measures
History and examination are key in the clinical approach. 
These will provide insights into the aetiology, rate of 
development, clinical impact and contributing co-morbidities, 
all factors important in a patient-focused approach to 
management. The appropriate clinical environment for the 
management of hyponatraemia is the one that matches 
the clinical needs of the patient. Management of 
hyponatraemia in a patient with significant neurological 
morbidity in whom plasma sodium is being raised over 
hours requires close clinical and biochemical observation. 
This is best achieved in a high-dependency setting. 
Cerebral oedema and coma associated with hyponatraemia 
may need supportive management with assisted ventilation. 
The use of mannitol in this situation can complicate the 
monitoring of biochemical response as it introduces 
another osmolyte that clinicians need to be aware of 
when interpreting electrolyte profiles.
Data suggest that an increase in plasma sodium of no more 
than 8–10 mmol/l/24 hours is safe. Target rates of change 
expressed as mmol/l/hr are not helpful as they set an 
expectation of fixed incremental change and move the 
focus away from clinical endpoints. There may be situations 
where a relatively rapid rise in plasma sodium of 2–4 
mmol/l over 2–4 hours is needed to reduce intracerebral 
pressure in the acute setting. This approach is appropriate 
as long as this rate of change is not maintained and the 
24-hour limit is not exceeded. Plasma sodium may rise 
faster than 2 mmol/l/hr during ‘autocorrection’ of 
hyponatraemia when an underlying cause has simply been 
removed, for example a correction of glucocorticoid 
insufficiency or withdrawal of excess desmopressin. 
Osmotic demyelination can still occur in these circumstances. 
It is important to consider actively controlling the rate of 
rise of plasma sodium in such situations.
Patients with mild or moderate symptoms and signs
The situation is such that the clinician may have time to 
make a diagnosis, identify and address contributing 
factors if possible and then, if needed, introduce a 
focused intervention based on aetiology (e.g. 
glucocorticoid replacement; see Table 5). The majority of 
patients will have circulating volume depletion or SIAD. 
Where these are due to drug treatments, the removal of 
the causal agent may be sufficient to normalise sodium. 
There will be some cases where the causal agent cannot 
be removed or where there is an alternative diagnosis.
Fluid challenge in hypovolaemic hyponatraemia
Mild to moderate hypovolaemia can be difficult to 
diagnose clinically and low urine sodium excretion (<20 
mmol/l) may be unreliable as a diagnostic test in the face 
of diuretic use or renin-angiotensin system blockade. If 
volume depletion is suspected, a moderate intravenous 
fluid challenge with 0.5–1 l N-saline over 2–4 hours may 
be both diagnostic and therapeutic.
Hyponatraemia
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FIGURE 1 Algorithm for the management of hyponatraemia.
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Diagnostic testing
Fluid restriction
Fluid restriction of 0.5–1 l/day is a reasonable initial 
intervention when excess plasma water is suspected and 
when the clinical condition is not critical. The higher the 
baseline urine osmolality, the less likely is fluid restriction 
to be effective. In patients with primary polydipsia, 
reduction in fluid intake remains the most reasonable 
approach.  All fluids need to be included in the restriction. 
As SIAD is associated with negative sodium balance, 
sodium intake needs to be maintained. Several days of 
restriction may be required before sodium levels rise 
and a negative fluid balance needs to be confirmed 
through appropriate monitoring.
Patients with significant coma or seizures
Hypertonic sodium chloride
Treatment with hypertonic sodium chloride addresses the 
reduction of plasma sodium concentration simply and 
directly. It is preferable to 0.9% saline as it allows more 
sodium to be given more quickly and with less volume. 
However, it is not without problems. There are numerous 
models with which to estimate total body water excess 
or total body sodium deficit in hyponatraemia. The utility 
of these models in day-to-day practice is limited if the 
concept of partial correction to clinical endpoints is 
accepted and further compromised by the use of 
asymmetric correction rates, with a proportionately 
larger increase in plasma sodium of some 2–4 mmol/l in 
the first 1–4 hours of intervention followed by a slower 
rise of 4–6 mmol/l in the following 20 hours.
An alternative stepped approach using the clinical and 
biochemical impact of a 100-ml bolus of 3% sodium 
chloride (with the aim of increasing plasma sodium by 
2 mmol/l increments) can be used.
Avoidance of over-correction is critical. Intervention 
with hypertonic fluid should be stopped when the 
defined clinical target or a sodium concentration of 125 
mmol/l is reached, whichever is first. Increasing plasma 
sodium to 125 mmol/l is likely to reduce the risk of 
significant neurological deterioration while minimising 
the risk of precipitating osmotic demyelination. The rate 
of change of plasma sodium must remain within the 
limits of 8–10 mmol/l per 24 hours. Hypertonic sodium 
chloride (3%) has largely replaced 5% sodium chloride. If 
hypertonic sodium chloride cannot be given safely, it 
should not be given.
Management of persistent hyponatraemia
Hyponatraemia may persist or recur after initial 
intervention. It is important that the differential diagnosis 
is reviewed and the basis for intervention reconsidered. 
However, SIAD and chronic volume depletion may require 
alternative approaches. In SIAD, fluid restriction may be 
only partly effective or may prove non-sustainable. In 
chronic persisting volume depletion, liver or cardiac 
dysfunction may persist and drug therapy exacerbating 
hyponatraemia may need to continue. Clinical decisions 
may have to balance the merits of incremental intervention 
with those of tolerating mild, persisting hyponatraemia.
Demeclocycline and lithium
Demeclocycline is effective in the management of 
hyponatraemia of SIAD. It produces a form of nephro-
genic diabetes insipidus and so increases renal water 
loss, even in the presence of high concentrations of 
AVP. Treatment is 600–1,200 mg/day in divided doses. 
There is a lag time of some 3–4 days in onset of action. 
Dose adjustment needs to take this into account. 
Renal function needs to be monitored closely and 
treatment stopped if significant renal impairment 
develops. Lithium has similar effects to demeclocycline. 
The effect of lithium is less consistent and it has more 
adverse effects.
Urea
Urea can be used to treat persisting hyponatraemia of 
SIAD. Active orally at doses of 30 g/day, urea improves 
hypo-osmolality by increasing renal free water excretion 
and decreasing urinary sodium. Even if only partially 
effective, it can allow reduction in water restriction.
Vasopressin receptor antagonists
Vasopressin receptor (VR) antagonists are a rational 
approach to the management of hyponatraemia mediated 
through the action of AVP.  The recent development of 
non-peptide VR antagonists (the vaptans) brings this 
possibility closer. There are three VR subtypes: V1a, V1b 
and V2. The effects of AVP on renal free water excretion 
are mediated by the V2-R. V2-R antagonists are classified 
as either selective (V2-R specific) or non-selective (V2- 
and V1a antagonism). Both increase renal water excretion 
without a significant impact on renal electrolyte loss. 
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Purpose Diagnostic test
Clinical 
baseline
Plasma Na+
Weight
Plasma osmolality
Urine osmolality
To confirm 
hypovolaemia
Lying and standing blood pressure
Full blood count
Plasma urea and creatinine
Plasma glucose
Plasma urate
Serum albumin and liver function
Urine Na+
To exclude 
endocrine 
causes
Plasma cortisol
If <450 nmol/l, consider short synacthen test
Free thyroxine and thyroid-stimulating hormone
To exclude 
other causes
Consider sepsis screen
To investigate 
basis of SIAD
Chest X-ray
TABLE 5 Diagnostic testing in hyponatraemia
Both are effective in the treatment of hyponatraemia 
associated with normal or increased plasma volume. 
The place of VR antagonists in the management of 
hyponatraemia is currently under development. 
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KEY POINTS
Hyponatraemia is associated with increased mortality • 
and morbidity in patients with heart failure, liver 
disease and acute neurological syndromes.
Hyponatraemia is often multifactorial. • 
Clinical presentations are diverse, reflecting a number • 
of influences, including the rate of development, scale, 
neurophysiological adaptive capacity and the influence 
of co-morbidities.
Management requires a systematic approach based • 
on clinical presentation.
The regulation of sodium balance, water balance and • 
circulating volume are linked and are best viewed as 
overlapping, co-ordinated neuro-humoral systems.
Osmolar criteria for syndrome of inappropriate • 
antidiuresis (SIAD) are met simply if urine is not 
maximally dilute in the face of coincident 
hyponatraemia.
Many drugs used in everyday clinical practice cause • 
SIAD and drug histories are an important part of the 
clinical assessment of patients presenting with 
hyponatraemia.
1.  Hyponatraemia is found in which one of the 
following percentages of non-selected 
emergency admissions to hospital in the UK?
A. 10%
B. 20%
C. 5%
D. 30%
E. 40%
2.  The management of patients presenting with 
hyponatraemia should be primarily based on 
which one of the following?
A. The plasma sodium concentration.
B. The rate of onset of hyponatraemia.
C. The clinical status of the patient.
D. The blood pressure of the patient.
E. The presence or absence of co-morbidity.
3.  Syndrome of inappropriate antidiuresis is 
characterised by which one of the following 
features?
A. Urine sodium concentration <20 mmol/l.
B. Plasma osmolality that exceeds urine osmolality.
C. Reduced plasma volume.
D. Urine sodium concentration >20 mmol/l.
E. Hypotension.
4.  When correcting hyponatraemia, which one of 
the following statements best describes the 
desired rate of increase in plasma sodium? 
A. Plasma sodium should be corrected to normal  
over 48 hours.
B. Plasma sodium should rise at no more than 8–10 
mmol/l per 24 hours.
C. Plasma sodium should be brought rapidly to 125 mmol/l.
D. Plasma sodium should be corrected at a steady rate 
until it is in the normal range.
E. Plasma sodium should be corrected to normal as quickly 
as possible if hyponatraemia has developed rapidly.
5.  Which one of the following statements best 
describes the use of hypertonic sodium chloride 
to correct hyponatraemia?
A. It should be used in all patients with symptomatic 
hyponatraemia.
B. It must be given at a constant rate to achieve normal 
sodium levels.
C. It must be used in a high-dependency setting with close 
clinical and biochemical monitoring.
D. It can only be used in patients with hypovolaemia.
E. Treatment should continue until normal plasma sodium 
concentration is achieved.
This paper was originally published as part of the Acute Medicine 
module in the RCPE Online Continuing Medical Education 
Programme. Online CME, including the anwers to these questions, 
is available to Fellows and Members at: http://www.rcpe.ac.uk
